康希诺生物股份公司 关于召开2024年年度股东大会的通知 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 一、 召开会议的基本情况 （一） 股东大会类型和届次 2024年年度股东大会 证券代码：688185 证券简称：康希诺 公告编号：2025-014 （四） 现场会议召开的日期、时间和地点 召开日期时间：2025 年 6 月 4 日 13 点 30 分 召开地点：天津市河东区卫国道 126 号天津东凯悦酒店二层悦宾厅 1 （五） 网络投票的系统、起止日期和投票时间。 网络投票系统：上海证券交易所股东大会网络投票系统 网络投票起止时间：自2025 年 6 月 4 日 至2025 年 6 月 4 日 采用上海证券交易所网络投票系统，通过交易系统投票平台的投票时间为股 东大会召开当日的交易时间段，即 9:15-9:25，9:30-11:30，13:00-15:00；通过互 联网投票平台的投票时间为股东大会召开当日的 9:15-15:00。 （六） 融资融券、转融通、约定购回业务账户和沪股通投资者的投票程序 股东大 ...

Financial Performance - The company's revenue for Q1 2025 was CNY 137,160,578.06, representing a year-over-year increase of 20.02% compared to CNY 114,282,281.78 in the same period last year[4]. - The net loss attributable to shareholders for the period was CNY 11,545,431.51, a significant improvement from a loss of CNY 170,095,866.61 in the previous year[4]. - Total operating revenue for Q1 2025 was ¥137,160,578.06, an increase of 20.00% compared to ¥114,282,281.78 in Q1 2024[18]. - Net profit for Q1 2025 was a loss of ¥11,545,431.51, an improvement from a loss of ¥174,882,984.28 in Q1 2024[19]. - The total comprehensive loss for Q1 2025 was ¥11,549,283.95, an improvement from a loss of ¥174,560,182.55 in Q1 2024[19]. Cash Flow - The net cash flow from operating activities was a net outflow of CNY 13,801,882.53, which is an improvement of CNY 94,393,791.82 compared to the previous year's outflow[7]. - Cash flow from operating activities showed a net outflow of ¥13,801,882.53 in Q1 2025, compared to a net outflow of ¥108,195,674.35 in Q1 2024[21]. - Cash flow from investing activities resulted in a net outflow of ¥437,359,085.65 in Q1 2025, contrasting with a net inflow of ¥275,011,228.44 in Q1 2024[22]. - Cash and cash equivalents at the end of Q1 2025 were ¥1,055,668,836.98, down from ¥2,374,907,374.57 at the end of Q1 2024[22]. Research and Development - Research and development (R&D) expenses totaled CNY 88,924,234.66, a decrease of 28.48% from CNY 124,328,450.39 in the same period last year, with R&D expenses accounting for 64.83% of revenue, down 43.96 percentage points[4][7]. - Research and development expenses were ¥72,712,590.56 in Q1 2025, down 25.00% from ¥96,745,611.33 in Q1 2024[18]. - The company continues to focus on enhancing R&D efficiency and integrating resources across different pipelines to drive future growth[7]. Assets and Liabilities - The total assets at the end of the reporting period were CNY 7,820,387,409.65, a decrease of 1.73% from CNY 7,958,132,235.38 at the end of the previous year[5]. - The company's current assets totaled CNY 4,134,286,329.53, down from CNY 4,282,490,715.65, indicating a decrease of about 3.45%[13]. - The company's total liabilities were CNY 2,921,615,159.54, down from CNY 3,048,260,581.65, showing a reduction of around 4.17%[15]. - The total equity attributable to the owners of the parent company was CNY 4,898,772,250.11, slightly decreasing from CNY 4,909,871,653.73, a change of about 0.23%[15]. Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 17,828[9]. - The company has not reported any significant changes in its major shareholders or their participation in margin trading activities[11]. Profitability Metrics - The weighted average return on equity improved by 3.04 percentage points to -0.24% from -3.28% in the previous year[4]. - The company's gross profit margin improved by 23.14 percentage points due to optimized production capacity and cost control measures[7]. - The company's inventory increased to CNY 322,559,055.80 from CNY 283,414,610.09, marking an increase of approximately 13.80%[13]. - The company's short-term borrowings decreased to CNY 213,622,195.45 from CNY 377,348,417.32, a reduction of about 43.45%[15]. - The company's long-term borrowings increased to CNY 1,114,926,712.74 from CNY 1,098,538,320.81, reflecting an increase of approximately 1.49%[15].

Core Viewpoint - The impact of the U.S. tariff policy on Chinese pharmaceutical companies is relatively limited, with many companies reporting normal operations and minimal effects from the tariffs [1][2][3][4][5]. Company Responses - Heng Rui Pharmaceutical stated that overseas sales account for only 2.56% of its revenue, indicating that U.S. tariffs will have a minimal impact on its business [1]. - Han Yu Pharmaceutical emphasized its diversified market layout, which mitigates risks from single market policy changes, and reported no significant impact from the tariffs [2]. - WuXi AppTec acknowledged that tariffs would have some effect but deemed it manageable, highlighting their optimized supply chain and global presence [3]. - Kang Tai Biological reported no exports to the U.S. and is focusing on markets along the Belt and Road, indicating a strategic shift to other regions [4]. - Mindray Medical confirmed that while some raw materials are imported from the U.S., they are taking measures to ensure supply safety and view the tariff impact as a one-time issue [4]. Industry Trends - The Chinese vaccine industry is rapidly developing, with companies like CanSino Biologics transitioning from followers to leaders in vaccine technology, focusing on domestic innovation [6][7]. - The overall sentiment among companies is that the tariff policy presents an opportunity for domestic product substitution, with many firms prepared to adapt to changing market conditions [5][8]. - Companies are increasingly focusing on technological innovation and expanding into emerging markets to counteract potential supply chain disruptions caused by tariffs [5][6][7].

Revenue and Profitability - The company's revenue for the first quarter reached RMB 137,160,578.06, representing a year-on-year increase of 20.02% compared to RMB 114,282,281.78[6]. - The net loss attributable to shareholders for the quarter was RMB 11,545,431.51, a significant improvement from a loss of RMB 170,095,866.61 in the same period last year, narrowing the loss by 88.41%[14][15]. - The gross profit margin improved by 23.14 percentage points due to optimized production capacity and cost reduction measures[16]. - The basic and diluted earnings per share for the quarter were both RMB (0.05), compared to RMB (0.69) in the same period last year[6]. - The company confirmed a net loss attributable to shareholders after excluding non-recurring gains and losses of RMB 55,234,681.60, compared to RMB 178,676,681.71 in the previous year[6][15]. - In Q1 2025, the company reported a total comprehensive loss of CNY 11,549,283.95, compared to a loss of CNY 169,773,064.88 in Q1 2024, indicating a significant improvement[32]. Research and Development - Research and development expenses totaled RMB 88,924,234.66, a decrease of 28.48% from RMB 124,328,450.39 in the previous year, with R&D expenses accounting for 64.83% of revenue[8]. - The proportion of R&D investment to operating income decreased by 43.96 percentage points, while total R&D investment decreased by 28.48% year-on-year, despite a 20.02% increase in operating income, indicating improved R&D efficiency[17]. - The company is focusing on integrating R&D resources and enhancing potential synergies across different pipelines to control R&D expenditures effectively[17]. Cash Flow and Financial Management - The company reported a net cash flow from operating activities of RMB (13,801,882.53), compared to RMB (108,195,674.35) in the previous year, indicating improved cash flow management[6]. - The net cash flow from operating activities for the reporting period was a net outflow of ¥13,801,882.53, a decrease of ¥94,393,791.82 compared to the same period last year, with operating cash inflow increasing by ¥59,603,047.08 due to higher sales revenue and collections of the brand Manhaixin®[17]. - Cash inflow from operating activities increased to CNY 235,251,379.47 in Q1 2025, up from CNY 175,648,332.39 in Q1 2024, reflecting a growth of approximately 34%[34]. - The company recorded cash outflow from investing activities of CNY 437,359,085.65 in Q1 2025, compared to an inflow of CNY 275,011,228.44 in Q1 2024, indicating a shift in investment strategy[36]. - The company incurred total cash outflows from financing activities of CNY 334,582,241.70 in Q1 2025, compared to CNY 168,104,615.34 in Q1 2024, indicating increased financing activities[36]. Assets and Liabilities - The total assets at the end of the reporting period were RMB 7,820,387,409.65, a decrease of 1.73% from RMB 7,958,132,235.38 at the end of the previous year[8]. - Total liabilities as of March 31, 2025, were RMB 2,921,615,159.54, down from RMB 3,048,260,581.65 as of December 31, 2024[26]. - Total equity attributable to shareholders as of March 31, 2025, was RMB 4,898,772,250.11, slightly down from RMB 4,909,871,653.73 as of December 31, 2024[26]. - The company reported other income of RMB 45,863,689.09 in Q1 2025, a significant increase from RMB 8,591,840.84 in Q1 2024[30]. Shareholder Information - The top ten shareholders held a total of 39.55% of shares, with HKSCC NOMINEES LIMITED being the largest shareholder with 97,857,297 shares[19]. - The company has not reported any changes in the participation of major shareholders in securities lending activities during the reporting period[21].

Financial Performance - The company reported a basic earnings per share of -0.0500 yuan for Q1 2025, a significant improvement of 92.75% compared to -0.6900 yuan in Q1 2024 [1] - Revenue for Q1 2025 was 1.37 billion yuan, representing a 20.18% increase from 1.14 billion yuan in Q1 2024 [1] - The net profit for Q1 2025 was -0.12 billion yuan, showing a 92.94% improvement from -1.7 billion yuan in Q1 2024 [1] - The return on equity for Q1 2025 was -0.24%, a notable improvement from -3.28% in Q1 2024 [1] Shareholder Information - The top ten unrestricted shareholders collectively hold 17,638.31 million shares, accounting for 71.28% of the circulating shares, with a decrease of 81.52 million shares compared to the previous period [2] - HKSCC NOMINEES LIMITED remains the largest shareholder with 9,785.73 million shares, representing 39.55% of the total share capital [3] - The advanced manufacturing industry investment fund (limited partnership) saw a decrease of 81.52 million shares [3] Dividend Distribution - The company has announced that there will be no distribution or transfer of dividends this time [4]

Core Viewpoint - The performance of several vaccine companies in China is significantly declining in 2024 due to industry policy adjustments, decreased public willingness to vaccinate, and changing market demands, leading to a challenging environment for the industry [1] Financial Performance - The average revenue of vaccine companies in 2024 is 7.131 billion yuan, down 21.63% from 9.099 billion yuan in 2023, while the average net profit is 788 million yuan, a decrease of 35.60% from 1.222 billion yuan in 2023 [1] - Companies like Zhifei Biological, Wantai Biological, and Hualan Biological reported revenue declines exceeding 50%, while Watson Biological, Baike Biological, and Jindike saw declines of over 30% [1] - Kangxino's revenue increased by over 130% due to its quadrivalent meningococcal conjugate vaccine, benefiting from the resolution of global public health events [1] Price Competition Impact - The price war among vaccine products, particularly HPV, influenza, and pneumonia vaccines, has severely impacted net profits, with Wantai Biological, Kangtai Biological, Hualan Biological, and Zhifei Biological experiencing declines of 91.49%, 76.59%, 76.10%, and 74.99% respectively [2] - Wantai Biological's revenue for 2024 is 2.245 billion yuan, down 59.25%, and its net profit is 106 million yuan, down 91.49% [6] - Watson Biological's revenue is 2.821 billion yuan, a decline of 31.41%, with a net profit of 142 million yuan, down 66.10% [6] Market Dynamics - The domestic vaccine market is becoming increasingly competitive, with many companies focusing on traditional products and facing challenges from product homogeneity and market saturation [3] - The overall vaccination rate in China is low, with only about 3% for influenza vaccines, indicating significant growth potential in the market despite current pressures [7] R&D and Innovation - Companies are increasing R&D investments, with Zhifei Biological investing 1.391 billion yuan in 2024, and several companies allocating over 20% of their revenue to R&D [8] - New vaccine technologies, including mRNA and DNA vaccines, are emerging, which could lead to breakthroughs in disease prevention and treatment [9] International Expansion - Many vaccine companies are pursuing international markets, with Kangxino and Baike Biological successfully exporting products to various countries [10][11] - Watson Biological reported overseas revenue of 570 million yuan in 2024, a year-on-year increase of approximately 98% [11] - The global human vaccine market is projected to grow significantly, with emerging markets providing opportunities for Chinese vaccine companies due to their competitive pricing [12][13]

登录新浪财经APP 搜索【信披】查看更多考评等级 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担个别及连带责任。 重要内容提示： ●会议召开时间：2025年4月30日（星期三）16:00-17:00 ●会议召开地点：上海证券交易所上证路演中心 （一）会议召开时间：2025年4月30日（星期三）16:00-17:00 （二）会议召开地点：上证路演中心 （三）会议召开方式：上证路演中心网络互动 三、 参加人员 （网址：http://roadshow.sseinfo.com） ●会议召开方式：上证路演中心网络互动 ●投资者可于2025年4月23日（星期三）至4月29日（星期二）16:00前登录上证路演中心网站首页点 击"提问预征集"栏目或通过公司投资者关系邮箱（ir@cansinotech.com）进行提问。公司将在说明会上 对投资者普遍关注的问题进行回答。 康希诺生物股份公司（以下简称"公司"）已于2025年3月26日发布2024年年度报告，并将于2025年4月30 日发布2025年第一季度报告。为便于广大投资者更全面深入地了解公司经营成果 ...

证券代码：688185 证券简称：康希诺 公告编号：2025-013 康希诺生物股份公司 关于召开 2024 年度暨 2025 年第一季度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示： （网址：http://roadshow.sseinfo.com） 康希诺生物股份公司（以下简称"公司"）已于 2025 年 3 月 26 日发布 2024 年年度报告，并将于 2025 年 4 月 30 日发布 2025 年第一季度报告。为便于广大 投资者更全面深入地了解公司经营成果、财务状况，公司计划于 2025 年 4 月 30 日（星期三）16:00-17:00 举行 2024 年度暨 2025 年第一季度业绩说明会，就投资 者关心的问题进行交流。 一、 说明会类型 本次投资者说明会以网络互动形式召开，公司将针对 2024 年度暨 2025 年第 一季度的经营成果及财务指标的具体情况与投资者进行互动交流和沟通，在信息 披露允许的范围内就投资者普遍关注的问题进行回答。 二、 说明会召开的时间、地点 会 ...

Financial Performance - Total revenue for 2024 reached RMB 824.884 million, a significant increase from RMB 345.182 million in 2023, representing a growth of 139.2%[7] - The company reported an operating loss of RMB 403.39 million for 2024, an improvement compared to the operating loss of RMB 2.035 billion in 2023[7] - The company reported a gross profit of approximately RMB 580.5 million, recovering from a gross loss of RMB 876.0 million in 2023[63] - Revenue from the cerebrospinal meningitis vaccine product reached RMB 793.8 million in 2024, up from RMB 561.7 million in 2023[60] - Other income decreased by 44.5% to approximately RMB 109.5 million in 2024, primarily due to a reduction in government subsidies[64] - Financial income decreased from approximately RMB 563 million for the year ended December 31, 2023, to approximately RMB 222 million for the year ended December 31, 2024, primarily due to a reduction in financial income of approximately RMB 362 million[70] - Income tax expense for the year ended December 31, 2024, was approximately RMB 25 million, a decrease from approximately RMB 115 million in 2023, due to the write-off of deferred tax assets[71] Assets and Liabilities - Total assets decreased to RMB 7.958 billion in 2024 from RMB 9.319 billion in 2023, a decline of 14.6%[7] - The company’s total liabilities decreased to RMB 3.048 billion in 2024 from RMB 4.031 billion in 2023, a reduction of 24.4%[7] - The company’s total equity decreased to RMB 4.910 billion in 2024 from RMB 5.287 billion in 2023, a decline of 7.1%[7] - Non-current assets were reported at RMB 3.676 billion in 2024, down from RMB 4.138 billion in 2023, indicating a decrease of 11.1%[7] - Cash and cash equivalents decreased by 24% from approximately RMB 20,470 million as of December 31, 2023, to approximately RMB 15,565 million as of December 31, 2024, mainly due to cash outflows from operating activities and loan repayments[87] - Total current liabilities decreased from approximately RMB 25,918 million as of December 31, 2023, to approximately RMB 17,720 million as of December 31, 2024, reflecting a reduction in borrowings and other payables[87] Vaccine Development and Commercialization - The sales revenue from the four-valent meningococcal conjugate vaccine, Manhaixin®, and the bivalent meningococcal conjugate vaccine, Meinaixi®, amounted to approximately RMB 793.8 million in 2024, reflecting a year-on-year growth of 41.3%[9] - The company plans to expand the age range for the Manhaixin® vaccine from children aged 3 months to 3 years to those aged 3 months to 6 years, pending regulatory approval[9] - The company is set to launch a new product, a 13-valent pneumonia combined vaccine, in 2025, with the registration application already accepted in 2024[10] - The company has initiated Phase II/III clinical trials for a component DTP vaccine for adolescents and adults, and the registration application for the infant DTP vaccine has been accepted and prioritized for review[10] - The company has received over $19 million in funding for the development of a recombinant poliovirus vaccine, highlighting its role in improving global public health[12] - The company has obtained product registration for its vaccine in Indonesia and is conducting clinical trials for safety and immunogenicity in the 18-55 age group[13] - The company is collaborating with the National Institute of Biotechnology Malaysia to advance the development of an mRNA polyvalent influenza vaccine[13] - The company aims to establish long-term strategic partnerships based on its diverse product pipeline and is preparing for WHO prequalification to explore international procurement opportunities[14] - The company has transformed from a biotechnology company to a biopharmaceutical company, enhancing its self-sustaining capabilities as more products enter commercialization[14] - The company has a broad vaccine portfolio addressing over ten disease areas, with five commercialized products as of the report date[18] Research and Development - The company has improved the production technology of the investigational PCV13i vaccine, achieving good safety and immunogenicity in its Phase III clinical trial[29] - The company has received GMP certification for its Ad5-EBOV vaccine, which is the first Ebola vaccine approved in China for emergency use[28] - The company is advancing its pipeline of innovative vaccines, including mRNA-based influenza vaccines and other combination vaccines[20] - The company's new drug application for PCV13i has been accepted by the National Medical Products Administration, with expectations to obtain approval by 2025[30] - The PBPV vaccine, currently in Phase I clinical trials, shows good safety in adults and the elderly, with significant antibody responses observed[32] - The infant DTcP vaccine's new drug application has been accepted, with ongoing Phase III clinical trials and a summary report already obtained[35] - The tetanus vaccine has initiated Phase III clinical trials, with a new drug application expected to be approved in the first half of 2026[40] - The company has secured exclusive global rights from McMaster University for the development of a tuberculosis booster vaccine, with promising results from Phase I trials[41] - The PBPV vaccine aims to provide broader coverage than existing PPV23 and PCV13 products, targeting over 90 serotypes of pneumonia[31] - The company plans to strengthen clinical data for the infant DTcP vaccine in 2025 to expedite the review process[35] Corporate Governance - The company emphasizes the importance of independent judgment and oversight from its board members, enhancing corporate governance standards[106][107][108] - The board comprises members with diverse backgrounds in finance, healthcare, and management, contributing to a well-rounded decision-making process[109][110] - The company is focused on maintaining high standards of corporate governance through experienced independent directors and supervisors[112] - The company has adopted all applicable provisions of the corporate governance code as per the Hong Kong Listing Rules Appendix C1[120] - The company confirmed that all directors and supervisors complied with the standard code during the reporting period[121] - The company has established specific service contracts for all directors, with terms lasting until the current board's three-year term expires[133] - The nomination committee will identify suitable candidates to fill any board vacancies based on required skills and experience[134] - The company will continue to assess whether the roles of chairman and CEO should be separated in the future[129] - The company has maintained compliance with the requirement of having at least three independent non-executive directors on the board[130] - The board of directors is responsible for leading and monitoring the company, ensuring effective internal controls and risk management systems[136] Market Strategy and Expansion - The company plans to enhance its marketing efforts and strengthen professional academic promotion to increase public awareness of vaccines[57] - The company aims to expand its market presence in Southeast Asia, the Middle East, and Latin America through strategic acquisitions and partnerships[58] - The company is actively expanding its commercialization efforts, focusing on key clinical decision-makers and vaccination points to enhance market presence[55] - The company has a robust strategy for market expansion and product development in the biopharmaceutical sector[102] - The company is committed to providing high-quality, innovative, and accessible vaccines globally as part of its mission[183] Human Resources and Corporate Culture - The company has established a training program for new employees to enhance understanding of corporate culture and compliance[184] - The company aims to maintain a gender ratio among employees, with male employees accounting for 48.6% and female employees accounting for 51.4%[165] - The board currently consists of 7 members, including 3 executive directors, 1 non-executive director, and 3 independent non-executive directors, with 1 female director and 6 male directors[163] - The company is committed to achieving gender equality on the board as a long-term goal[164] - The company has established a whistleblowing policy that encourages reporting of misconduct, ensuring confidentiality and protection for whistleblowers[170] - The company emphasizes a corporate culture focused on innovation, quality, and responsibility, with a vision of "Innovation without end, a world without epidemics"[183]

康希諾生物股份公司 （於中華人民共和國註冊成立的股份有限公司） 香港交易及結算所有限公司及香港聯合交易所有限公司對本通告的內容概不負 責，對其準確性或完整性亦不發表任何聲明，並明確表示，概不就因本通告全部 或任何部分內容所產生或因依賴該等內容而引致的任何損失承擔任何責任。 CanSino Biologics Inc. 香港，2025年4月15日 於本通告日期，本公司董事會包括執行董事Xuefeng YU博士、Shou Bai CHAO博 士 及王靖女士；非執行董事李志成先生；以及獨立非執行董事桂水發先生、劉建忠 先生及張耀樑先生。 （股份代號：6185） 承董事會命 康希諾生物股份公司 Xuefeng YU 董事長 董事會會議通告 康 希 諾 生 物 股 份 公 司（「本公司」）董 事（「董 事」）會（「董事會」）謹 此 宣 佈，董 事 會 會 議將於2025年4月29日（星 期 二）舉 行，藉 以（其 中 包 括）考 慮 及 批 准 本 公 司 及 其 附 屬公司截至2025年3月31日止三個月的第一季度業績及其發佈。 ...